BIOMARKER:

ALK wild-type

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	atezolizumab Sensitive: C3 – Early Trials Nat Med - 2 weeks (New C3) atezolizumab Sensitive : C3 Nat Med - 2wk	atezolizumab Sensitive: C3 – Early Trials Nat Med - 2 weeks atezolizumab Sensitive : C3 Nat Med - 2 weeks - (New C3)
ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks (New B) atezolizumab Sensitive : B Cancer Med - 3wk	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks atezolizumab Sensitive : B Cancer Med - 3 weeks - (New B)
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B
ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	cemiplimab Sensitive: B - Late Trials cemiplimab Sensitive : B	cemiplimab Sensitive: B - Late Trials cemiplimab Sensitive : B
ALK wild-type	Lung Non-Small Cell Squamous Cancer	ALK wild-type	Lung Non-Small Cell Squamous Cancer	cemiplimab Sensitive: B - Late Trials cemiplimab Sensitive : B	cemiplimab Sensitive: B - Late Trials cemiplimab Sensitive : B
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	toripalimab Sensitive: C2 – Inclusion Criteria toripalimab Sensitive : C2	toripalimab Sensitive: C2 – Inclusion Criteria toripalimab Sensitive : C2
ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	tislelizumab Sensitive: C3 – Early Trials tislelizumab Sensitive : C3	tislelizumab Sensitive: C3 – Early Trials tislelizumab Sensitive : C3
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	AK112 Sensitive: C3 – Early Trials AK112 Sensitive : C3	AK112 Sensitive: C3 – Early Trials AK112 Sensitive : C3
ALK wild-type	Lung Cancer	ALK wild-type	Lung Cancer	crizotinib Sensitive: D – Preclinical crizotinib Sensitive : D	crizotinib Sensitive: D – Preclinical crizotinib Sensitive : D